WHO ICTRP trial
EUCTR2018-001807-35-FR · UNICANCER
EUCTR2018-001807-35-FR · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2018-001807-35-FR |
|---|---|
| Scientific title | Phase II study of maintenance anti-PD-L1 treatment with atezolizumab after chemo-radiotherapy for muscle-infiltrating bladder cancer patients not eligible for radical cystectomy: Bladder Sparing - Bladder Sparing |
| Primary sponsor | UNICANCER |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | France |
| Conditions | Patients older than =18 years, muscle-invasive bladder cancer unfit for radical cystectomy because of age, comorbidities, and/or patient’s refusal.;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Trade Name: Tecentriq Product Name: Atezolizumab Product Code: RO5541267 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ATEZOLIZUMAB Current Sponsor code: RO5541267 Other descriptive name: MPDL3280A… |
| Registration date | Aug 21, 2018 |
| Target size | 77 |
| Secondary IDs | GETUG-AFU35UC-0160-1715 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: